参考文献/References:
[1]温实,戴新武,黄丽娟,等.KR1B10与GPC-3免疫组化检测对肝细胞肝癌的诊断价值[J].现代生物医学进展,2015,15(32):6263-6265.[2]刘冲,唐浩,邓霖,等.血清miRNA-186,miRNA-30c在肝细胞性癌中诊断价值的研究[J].现代检验医学杂志,2016,31(6):44-47.[3]周新刚,张亮,王鹏,等.Arginase-1联合Glypican-3在肝细胞肝癌和非肝脏来源肿瘤鉴别诊断中的意义[J].临床与实验病理学杂志,2017,33(8):841-846.[4]晏文强,谢明水,刘杨.GP73、AFP-L3与GPC-3联合检测在原发性肝癌诊断中的临床价值[J].中国实验诊断学,2015,19(10):1651-1654.[5]王娟,张曙光,孙颖,等.免疫组化检测GPC-3与CK-19在肝细胞癌诊断中的应用价值[J].临床和实验医学杂志,2017,16(14):50-53.
相似文献/References:
[1]王利娜,赵雪梅,徐云霞,等.磁共振扩散张量成像在肝细胞癌及
肝转移瘤鉴别诊断价值研究[J].医学信息,2018,31(09):12.[doi:10.3969/j.issn.1006-1959.2018.09.004]
WANG Li-na,ZHAO Xue-mei,XU Yun-xia,et al.Diagnostic Value of Magnetic Resonance Diffusion Tensor Imaging in Hepatocellular Carcinoma and Liver Metastases[J].Medical Information,2018,31(23):12.[doi:10.3969/j.issn.1006-1959.2018.09.004]
[2]刘丽丽.CLCVP对肝细胞癌行腹腔镜肝叶切除手术相关指标及肝门阻断时间的影响[J].医学信息,2020,33(19):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
LIU Li-li.The Effect of CLCVP on the Operation-related Indexes and Port Occlusion Time in Patients with Hepatocellular Carcinoma Undergoing Laparoscopic Lobectomy[J].Medical Information,2020,33(23):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
[3]孙莹莹,龚先琼.中药单体治疗肝细胞癌的研究[J].医学信息,2021,34(09):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
SUN Ying-ying,GONG Xian-qiong.Study on the Treatment of Hepatocellular Carcinoma with Chinese Medicine Monomer[J].Medical Information,2021,34(23):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
[4]林思其,张泽鑫,夏睿琪,等.三种miRNA对肝癌预后预测的生物信息学分析模型[J].医学信息,2022,35(03):81.[doi:10.3969/j.issn.1006-1959.2022.03.019]
LIN Si-qi,ZHANG Ze-xin,XIA Rui-qi,et al.A Model of Three miRNA on the Prognosis Prediction of Hepatocellular Carcinomaby Bioinformatics Analysis[J].Medical Information,2022,35(23):81.[doi:10.3969/j.issn.1006-1959.2022.03.019]
[5]李一鸣,陈文翔,王 禹,等.肝癌预后模型的构建及其在免疫治疗中的作用研究[J].医学信息,2022,35(04):68.[doi:10.3969/j.issn.1006-1959.2022.04.018]
LI Yi-ming,CHEN Wen-xiang,WANG Yu,et al.The Construction of a Prognostic Model for Hepatocellular Carcinomaand its Role in Immunotherapy[J].Medical Information,2022,35(23):68.[doi:10.3969/j.issn.1006-1959.2022.04.018]
[6]徐帅帅,高 斌.TACE与阿帕替尼联合治疗中晚期肝细胞癌的疗效及安全性分析[J].医学信息,2022,35(06):116.[doi:10.3969/j.issn.1006-1959.2022.06.028]
XU Shuai-shuai,GAO Bin.Analysis of the Efficacy and Safety of TACE Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma[J].Medical Information,2022,35(23):116.[doi:10.3969/j.issn.1006-1959.2022.06.028]
[7]李文华,许传斌,崔景景,等.基于治疗前MR-T2WI影像组学特征预测肝细胞癌射频消融术后早期复发的价值[J].医学信息,2022,35(18):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
LI Wen-hua,XU Chuan-bin,CUI Jing-jing,et al.The Value of Predicting Early Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Based on Pre-treatment MR-T2WI Radiomics Features[J].Medical Information,2022,35(23):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
[8]彭莉蓉,黎村艳,史 杨.肿瘤微环境免疫细胞中差异lncRNA对肝细胞癌预后的预测价值[J].医学信息,2022,35(20):18.[doi:10.3969/j.issn.1006-1959.2022.20.005]
PENG Li-rong,LI Cun-yan,SHI Yang.The Predictive Value of Differential lncRNA in Tumor Microenvironment Immune Cells for the Prognosis of Hepatocellular Carcinoma[J].Medical Information,2022,35(23):18.[doi:10.3969/j.issn.1006-1959.2022.20.005]
[9]裴金仙,陈天狮,任巧晶,等.JAK2/STAT3通路在HBV相关肝细胞癌中表达及机制研究[J].医学信息,2022,35(24):59.[doi:10.3969/j.issn.1006-1959.2022.24.012]
PEI Jin-xian,CHEN Tian-shi,REN Qiao-jing,et al.The Expression and Mechanism of JAK2/STAT3 Pathway in HBV-related Hepatocellular Carcinoma[J].Medical Information,2022,35(23):59.[doi:10.3969/j.issn.1006-1959.2022.24.012]
[10]杨孟涛,汪 艇,杜 伟,等.miR-181b-5p靶向调控SPP1在肝细胞癌中过表达的临床意义及作用机制[J].医学信息,2022,35(24):79.[doi:10.3969/j.issn.1006-1959.2022.24.016]
YANG Meng-tao,WANG Ting,DU Wei,et al.Clinical Significance and Mechanism of miR-181b-5p Targeting to Regulate SPP1 Overexpression in Hepatocellular Carcinoma[J].Medical Information,2022,35(23):79.[doi:10.3969/j.issn.1006-1959.2022.24.016]